Trials / Completed
CompletedNCT04652557
Influence of Fampridine on Working Memory in Healthy Young Subjects
Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Prof. Dominique de Quervain, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
Proof of concept study on the acute effects on working memory of 10 mg fampridine SR as well as the effects after repeated administration of 10 mg twice daily (3.5 days). The hypothesis ist that fampridine improves working memory performance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fampridine SR | Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS). |
| DRUG | Placebo | no active component |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-01-26
- Completion
- 2023-01-26
- First posted
- 2020-12-03
- Last updated
- 2023-02-06
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04652557. Inclusion in this directory is not an endorsement.